TGN1412: From discovery to disaster

Journal of Young Pharmacists

Volumn 2, Issue 3, 2010, Pages 332-336

  Attarwala, H ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Clinical trials; Fialuridine; TGN1412

Indexed keywords

FIALURIDINE; TGN 1412;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SCREENING; DRUG SYNTHESIS; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LACTIC ACIDOSIS; LIVER TOXICITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING;

EID: 77955892579     PISSN: 09751483     EISSN: 09751505     Source Type: Journal    
DOI: 10.4103/0975-1483.66810     Document Type: Review

References (21)

1. Masteller EL, Warner MR, Tang Q, Tarbell KV, McDevitt H, Bluestone JA. Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol 2005;175:3053-9.
2. Hunig T. Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol 2007;95:111-48.
3. Lhder F, Huang Y, Dennehy KM, Guntermann C, Mller I, Winkler E, et al. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 2003;197:955-66.
4. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355:1018-28.
5. Hanke T. Lessons from TGN1412. Lancet 2006;368:1569-70.
6. Stebbings R, Poole S, Thorpe R. Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol 2009;20:673-7.
7. Schraven B, Kalinke U. CD28 superagonists: What makes the difference in humans? Immunity 2008;28:591-5.
8. Dayan CM, Wraith DC. Preparing for first-in-man studies: The challenges for translational immunology post-TGN1412. Clin Exp Immunol 2008;151:231-4.
9. Horvath CJ, Milton MN. The TeGenero incident and the Duff report conclusions: A series of unfortunate events or an avoidable event? Toxicol Pathol 2009;37:372-83.
10. Shamoo A, Woeckner E. Ethical flaws in the TeGenero trial. Am J Bioeth 2007;7:90-2.
11. Hansen S, Leslie RG. TGN1412: Scrutinizing preclinical trials of antibody-based medicines. Nature 2006;441:282.
12. Goodyear MD. Further lessons from the TGN1412 tragedy. BMJ 2006;333:270-1.
13. Tuma RS. Phase I antibody risks, trial safety examined. J Natl Cancer Inst 2006;98:956-8.
14. Weis JH. Allergy test might have avoided drug-trial disaster. Nature 2006;441:150.
15. Honkoop P, Scholte HR, de Man RA, Schalm SW. Mitochondrial injury. Lessons from the fialuridine trial. Drug Saf 1997;17:1-7.
16. Gallin JI. Principles and practice of clinical research. San Diego, CA: Academic Press. xv; 2002. p. 490.
17. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333:1099-105.
18. Richardson FC, Engelhardt JA, Bowsher RR. Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration. Proc Natl Acad Sci U S A 1994;91:12003-7.
19. Swartz MN. Mitochondrial toxicity-new adverse drug effects. N Engl J Med 1995;333:1146-8.
20. Lewis W, Griniuviene B, Tankersley KO, Levine ES, Montione R, Engelman L, et al. Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax). Lab Invest 1997;76:77-87.
21. Department of Health. Expert Scientific Group on phase one clinical trials: a consultation, 8 th June, 2010. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-063117 [last accessed 2010 Jun 8].